Neurocrine Biosciences (NBIX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurocrine Biosciences (NBIX)

NBIX 150.91

-0.8%

Dec 1 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (474)	1/30/2000 1:39:00 PM
From: Miljenko Zuanic	Read Replies (2) of 1834

NBIX should partner their GnRH antagonist program? Latest AMGN results: <<Amgen Inc. (AMGN), Thousand Oaks, Calif. Product: Abarelix Depot (PPI-149) Business: Cancer, Metabolic Therapeutic category: Signal transduction, Cell proliferation Target: GnRH Description: Lutenizing hormone releasing hormone (LHRH)/gona-dotropin releasing hormone (GnRH) antagonist Indication: Treat prostate cancer AMGN and partner Praecis Pharmaceuticals Inc. (Cambridge, Mass.) completed two Phase III trials of abarelix and said the results confirmed Phase II testing in which abarelix reduced androgen levels within 24 hours and produced a 50 percent reduction from baseline in prostate specific antigen (PSA) levels after one month in 79 percent of treated patients compared to 55 percent of patients receiving GnRH superagonist monotherapy (p=0.023). A safety study of abarelix is ongoing, and AMGN expects to submit a U.S. regulatory application in late 2000.>>

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next